STOCK TITAN

Commodore holds 5.5M RLMD shares, including 4.21M warrant shares (RLMD)

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Relmada Therapeutics reports beneficial ownership by Commodore Capital entities of 5,505,527 shares as of April 27, 2026. This total consists of 1,295,000 shares held and 4,210,527 shares issuable upon exercise of a Pre-Funded Warrant. The filing cites 104,890,223 shares outstanding as of March 16, 2026, implying a 5.1% stake based on that figure.

Positive

  • None.

Negative

  • None.

Insights

Commodore-affiliated funds report a 5.1% position in Relmada (5,505,527 shares, including warrant-convertible shares).

Commodore Capital LP and Commodore Capital Master LP, with principals Michael Kramarz and Robert Egen Atkinson, report combined beneficial ownership of 5,505,527 shares as of April 27, 2026, including 4,210,527 shares issuable on exercise of a Pre-Funded Warrant. The filing bases the percentage on March 16, 2026's reported 104,890,223 shares outstanding.

Cash-flow treatment and disposition plans are not stated in the excerpt; subsequent filings would show any sales or conversions.

Filing shows shared voting and dispositive power for the reported shares rather than sole control.

The cover data lists 0 sole voting power and 5,505,527 in shared voting and dispositive power across the Filers, indicating collective control through the investment manager and affiliated entities. The relationship is described as the Firm acting as investment manager to Commodore Master, with partners exercising investment discretion.

Material impact depends on future actions by these holders; timing and methods of any disposition are not disclosed in this excerpt.

Beneficial ownership 5,505,527 shares as of April 27, 2026
Currently held shares 1,295,000 shares component of the 5,505,527 total
Warrant-issuable shares 4,210,527 shares issuable upon exercise of a Pre-Funded Warrant
Shares outstanding used for percent 104,890,223 shares as of March 16, 2026
Percent of class 5.1% based on 104,890,223 shares outstanding
Pre-Funded Warrant financial
"issuable upon the exercise of the Pre-Funded Warrant"
A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.
Beneficially own regulatory
"the Firm may be deemed to beneficially own an aggregate of 5,505,527 Common stock"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Shared Dispositive Power regulatory
"Shared Dispositive Power 5,505,527.00"
Schedule 13G regulatory
"form_type: SCHEDULE 13G"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Commodore Capital report in RLMD?

Commodore-affiliated filers report beneficial ownership of 5,505,527 shares of RLMD as of April 27, 2026. That total includes 1,295,000 shares held and 4,210,527 issuable upon exercise of a Pre-Funded Warrant.

How was the 5.1% ownership percentage for RLMD calculated?

The percentage is based on 104,890,223 shares outstanding as of March 16, 2026. Using that figure, the filers' 5,505,527 shares represent 5.1% of the class as cited in the filing.

Who are the named filers for the RLMD Schedule 13G?

The filing lists Commodore Capital LP, Commodore Capital Master LP, Michael Kramarz, and Robert Egen Atkinson as joint filers, with the Firm acting as investment manager and the individuals as managing partners.

Do the filers report sole control over the RLMD shares?

No. The cover data shows 0 sole voting power and 5,505,527 in shared voting and dispositive power, indicating shared control among the Filers and related entities.

Are the 4,210,527 warrant-issuable shares currently outstanding?

Those 4,210,527 shares are described as issuable upon exercise of a Pre-Funded Warrant; they are included in the beneficial-ownership total but are not stated as outstanding as of the March 16, 2026 outstanding count.





75955J402

(CUSIP Number)
04/27/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Commodore Capital LP
Signature:Michael Kramarz
Name/Title:Managing Partner
Date:05/04/2026
Commodore Capital Master LP
Signature:Michael Kramarz
Name/Title:Authorized Signatory
Date:05/04/2026
Robert Egen Atkinson
Signature:Robert Egen Atkinson
Name/Title:Authorized Signatory
Date:05/04/2026
Michael Kramarz
Signature:Michael Kramarz
Name/Title:Authorized Signatory
Date:05/04/2026
Exhibit Information

Exhibit 1: Joint Filing Agreement